These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35716932)

  • 1. Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: A combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies.
    Sun M; Dubé MP; Hennessy T; Schultz CJ; Barhdadi A; Rhainds D; Hillis GS; Tardif JC
    Int J Cardiol; 2022 Sep; 363():20-22. PubMed ID: 35716932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction.
    Hennessy T; Soh L; Bowman M; Kurup R; Schultz C; Patel S; Hillis GS
    Am Heart J; 2019 Sep; 215():62-69. PubMed ID: 31284074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of low-dose colchicine in acute and chronic coronary syndromes: A systematic review and meta-analysis.
    Aimo A; Pascual Figal DA; Bayes-Genis A; Emdin M; Georgiopoulos G
    Eur J Clin Invest; 2021 Apr; 51(4):e13464. PubMed ID: 33251579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of the effect of colchicine on C-reactive protein in patients with acute and chronic coronary syndromes.
    Alam M; Kontopantelis E; Mamas MA; Savinova OV; Jhaveri A; Siddiqui E; Jhamnani S
    Coron Artery Dis; 2023 May; 34(3):210-215. PubMed ID: 36762630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial.
    Gholoobi A; Askari VR; Naghedinia H; Ahmadi M; Vakili V; Baradaran Rahimi V
    Inflammopharmacology; 2021 Oct; 29(5):1379-1387. PubMed ID: 34420187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Colchicine in Post-acute Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Diaz-Arocutipa C; Benites-Meza JK; Chambergo-Michilot D; Barboza JJ; Pasupuleti V; Bueno H; Sambola A; Hernandez AV
    Front Cardiovasc Med; 2021; 8():676771. PubMed ID: 34169101
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of colchicine on inflammatory markers in patients with coronary artery disease: A meta-analysis of clinical trials.
    Pan Z; Cheng J; Yang W; Chen L; Wang J
    Eur J Pharmacol; 2022 Jul; 927():175068. PubMed ID: 35644423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
    Bouabdallaoui N; Tardif JC; Waters DD; Pinto FJ; Maggioni AP; Diaz R; Berry C; Koenig W; Lopez-Sendon J; Gamra H; Kiwan GS; Blondeau L; Orfanos A; Ibrahim R; Grégoire JC; Dubé MP; Samuel M; Morel O; Lim P; Bertrand OF; Kouz S; Guertin MC; L'Allier PL; Roubille F
    Eur Heart J; 2020 Nov; 41(42):4092-4099. PubMed ID: 32860034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
    Samuel M; Tardif JC; Khairy P; Roubille F; Waters DD; Grégoire JC; Pinto FJ; Maggioni AP; Diaz R; Berry C; Koenig W; Ostadal P; Lopez-Sendon J; Gamra H; Kiwan GS; Dubé MP; Provencher M; Orfanos A; Blondeau L; Kouz S; L'Allier PL; Ibrahim R; Bouabdallaoui N; Mitchell D; Guertin MC; Lelorier J
    Eur Heart J Qual Care Clin Outcomes; 2021 Sep; 7(5):486-495. PubMed ID: 32407460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events in Patients With Myocardial Infarction: a Healthcare-Based Study.
    Carrero JJ; Andersson Franko M; Obergfell A; Gabrielsen A; Jernberg T
    J Am Heart Assoc; 2019 Jun; 8(11):e012638. PubMed ID: 31140334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease.
    Nidorf M; Thompson PL
    Am J Cardiol; 2007 Mar; 99(6):805-7. PubMed ID: 17350370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Colchicine in Reducing Inflammatory Biomarkers and Cardiovascular Risk in Coronary Artery Disease: A Meta-analysis of Clinical Trials.
    Sethuramalingam S; Maiti R; Hota D; Srinivasan A
    Am J Ther; 2023 May; 30(3):e197-e208. PubMed ID: 34264887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
    Roman YM; Hernandez AV; White CM
    Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of admission C-reactive protein levels on the development of poor myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction.
    Celik T; Iyisoy A; Kursaklioglu H; Turhan H; Kilic S; Kose S; Amasyali B; Isik E
    Coron Artery Dis; 2005 Aug; 16(5):293-9. PubMed ID: 16000887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States.
    Pagidipati NJ; Hellkamp AS; Sharma PP; Wang TY; Fonarow GC; Pencina M
    Am Heart J; 2018 Oct; 204():151-155. PubMed ID: 30121016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention.
    Schoos MM; Kelbæk H; Kofoed KF; Køber L; Kløvgaard L; Helqvist S; Engstrøm T; Saunamäki K; Jørgensen E; Holmvang L; Clemmensen P
    Am J Cardiol; 2011 Jun; 107(11):1597-603. PubMed ID: 21439539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral Inflammatory Biomarkers for Myocardial Infarction Risk: A Prospective Community-Based Study.
    Wu Z; Huang Z; Jin W; Rimm EB; Lichtenstein AH; Kris-Etherton PM; Wu S; Gao X
    Clin Chem; 2017 Mar; 63(3):663-672. PubMed ID: 28031418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
    Tardif JC; Kouz S; Waters DD; Bertrand OF; Diaz R; Maggioni AP; Pinto FJ; Ibrahim R; Gamra H; Kiwan GS; Berry C; López-Sendón J; Ostadal P; Koenig W; Angoulvant D; Grégoire JC; Lavoie MA; Dubé MP; Rhainds D; Provencher M; Blondeau L; Orfanos A; L'Allier PL; Guertin MC; Roubille F
    N Engl J Med; 2019 Dec; 381(26):2497-2505. PubMed ID: 31733140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response.
    Akodad M; Lattuca B; Nagot N; Georgescu V; Buisson M; Cristol JP; Leclercq F; Macia JC; Gervasoni R; Cung TT; Cade S; Cransac F; Labour J; Dupuy AM; Roubille F
    Arch Cardiovasc Dis; 2017; 110(6-7):395-402. PubMed ID: 28065445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High sensitive C-reactive protein and the risk of acute kidney injury among ST elevation myocardial infarction patients undergoing primary percutaneous intervention.
    Shacham Y; Leshem-Rubinow E; Steinvil A; Keren G; Roth A; Arbel Y
    Clin Exp Nephrol; 2015 Oct; 19(5):838-43. PubMed ID: 25492251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.